Elevar Logo for Common Use.png
Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma
30 mai 2024 07h00 HE | Elevar Therapeutics
Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment for uHCCFinal analysis...
Elevar Logo for Common Use.png
Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study at 2024 ASCO Gastrointestinal Cancers Symposium
18 janv. 2024 08h45 HE | Elevar Therapeutics
A post hoc analysis found the efficacy of camrelizumab plus rivoceranib was superior to sorafenib regardless of baseline liver function as measured by both albumin-bilirubin grade and Child-Pugh...
Elevar Logo for Common Use.png
Elevar Therapeutics Names Brian Cunningham Vice President of Sales and Kenneth Rankin Vice President of Market Access, Strengthening Commercial Leadership in Buildup to Launch
23 oct. 2023 08h45 HE | Elevar Therapeutics
FORT LEE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Hengrui's logo
Jiangsu Hengrui Pharma and Elevar Therapeutics Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC
17 oct. 2023 09h00 HE | Elevar Therapeutics
PRINCETON, N.J. and FORT LEE, N.J. Oct. 17, 2023 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma), one of China’s largest pharmaceutical companies based on market...
Elevar Logo for Common Use.png
Elevar Therapeutics and Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC
17 oct. 2023 09h00 HE | Elevar Therapeutics
FORT LEE, N.J. and PRINCETON, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated...
Global Communities R
Global Communities Rally around Third Deadliest Cancer – Liver Cancer
01 oct. 2023 10h30 HE | Global Liver Institute
Washington, DC, Oct. 01, 2023 (GLOBE NEWSWIRE) -- Today marks the start of Liver Cancer Awareness Month, which will feature the monthlong #OctoberIs4Livers multifaceted campaign led by Global Liver...
Logo.png
Hepatocellular Carcinoma Clinical Trial Analysis: DelveInsight Evaluates a Robust Pipeline as 90+ Influential Pharma Players to Set Foot in the Domain
26 juin 2023 13h00 HE | DelveInsight Business Research LLP
New York, USA, June 26, 2023 (GLOBE NEWSWIRE) -- Hepatocellular Carcinoma Clinical Trial Analysis: DelveInsight Evaluates a Robust Pipeline as 90+ Influential Pharma Players to Set Foot in the...
22157.jpg
AI in Oncology for Analytical Solutions Market - Global Forecast to 2033: Market to Grow at a CAGR of 35.11%
03 avr. 2023 10h18 HE | Research and Markets
Dublin, April 03, 2023 (GLOBE NEWSWIRE) -- The "AI in Oncology for Analytical Solutions Market by Cancer Type, by Component, and by Region - Global Forecast to 2023-2033" report has been added to ...
Elevar Logo for Common Use.png
Elevar Therapeutics to Present Clinically Supported Poster at AACR 2023 Demonstrating Rivoceranib as a Potent, and Most Selective, TKI for VEGFR-2
16 mars 2023 08h00 HE | Elevar Therapeutics
FORT LEE, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
22157.jpg
Interventional Oncology Global Market Report 2022: Favourable Government Policies and Technological Advancements Drive Sector
02 déc. 2022 08h28 HE | Research and Markets
Dublin, Dec. 02, 2022 (GLOBE NEWSWIRE) -- The "Interventional Oncology Market By Product: Global Opportunity Analysis and Industry Forecast, 2021-2031" report has been added to ...